Short Interest in Adlai Nortye Ltd. (NASDAQ:ANL) Increases By 89.5%

Adlai Nortye Ltd. (NASDAQ:ANL) was the recipient of a large growth in short interest during the month of February. As of February 28th, there was short interest totalling 7,200 shares, a growth of 89.5% from the February 13th total of 3,800 shares. Based on an average daily volume of 8,600 shares, the short-interest ratio is currently 0.8 days. Currently, 0.0% of the shares of the stock are sold short.

Adlai Nortye Price Performance

Shares of ANL stock opened at $2.19 on Friday. Adlai Nortye has a 12-month low of $1.85 and a 12-month high of $17.48. The firm has a 50-day moving average price of $2.15 and a 200 day moving average price of $2.25.

Adlai Nortye Company Profile

Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas.